Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.43 |
| ▸ | GABRP | O00591 | 6/20 | 0.43 |
| ▸ | GABRD | O14764 | 6/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.43 |
| ▸ | GABRE | P78334 | 6/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7092955 | 0.94 | POLB (0.56) | POLBLMNACYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL27594663 | 0.87 | LMNA (0.44) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL1019601 | 0.86 | CYP1A2 (0.59) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL12184767 | 0.83 | POLB (0.46) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL30445565 | 0.83 | POLB (0.46) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL13635198 | 0.83 | POLB (0.46) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL2960339 | 0.83 | POLB (0.50) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL480161 | 0.83 | MAPK1 (0.47) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL31390501 | 0.83 | MAPK1 (0.47) | POLBLMNACYP1A2GABRA1GABRG2 | |
| SCHEMBL6201965 | 0.81 | POLB (0.47) | POLBLMNACYP1A2GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116143804-B | Tetracyclic quinolone compound, pharmaceutically acceptable salt and application thereof | 核新生物医药(长春)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116143804-A | Tetracyclic quinolone compound, pharmaceutically acceptable salt and application thereof | 核新生物医药(长春)有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2305641-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305641-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7189851-B2 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | CALCRL, CALCR, CALCB | POLB 2621/4885LMNA 424/4885CYP1A2 3960/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | POLB 1610/4885LMNA 1815/4885CYP1A2 553/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | POLB 1676/4885LMNA 1884/4885CYP1A2 314/4885 |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | POLB 4796/4885LMNA 4382/4885CYP1A2 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.